A Look at Saudi Arabia’s Pharmaceutical Market in 2024

By Staff Writer

February 23, 2024

Introduction:

In the rapidly evolving pharmaceutical landscape, Saudi Arabia stands as a beacon of growth and innovation, particularly as the largest market of the Gulf Cooperation Council (GCC). A recent update from Pharma Boardroom aimed to shed light on the Saudi Pharma Market 2024, detailing the country’s strategic growth, local production, and biotech plans, and the prevalent public-private partnership (PPP) model.

Vision 2030: A New Era for Saudi Pharma

The Saudi government launched the Vision 2030 initiative in 2016. Its aim is to lessen the economy’s reliance on oil and to instigate economic reforms. This strategy has fostered a robust business environment. Multinational pharmaceutical companies such as Novartis, Pfizer, Sanofi, Merck, and GlaxoSmithKline have found it attractive. Projections suggest that by 2027, the Saudi pharma market will be worth USD 15.1 billion. This potential makes it an appealing hub for global pharmaceutical and biotech companies. 

Boosting Local Production

Saudi Arabia’s government has been actively supporting the local pharmaceutical production industry with a USD 3.4 billion investment plan in 2022. The goal is to strengthen health security and nurture local manufacturing potential. Pfizer, the first multinational pharma company to receive a “trading licence” in 2016, has ramped up production in Saudi Arabia. The Local Content and Government Procurement Authority (LCGPA) has facilitated industry localisation and knowledge transfers by signing several agreements. One agreement is a partnership with Saudi-based Jamjoom Pharma, and MSD to produce sitagliptin phosphate, a treatment for type 2 diabetes. Another involves a collaboration with Saudi and Japanese-owned SAJA for the manufacture of ticagrelor. The Saudi Press Agency reports that the financial impact of each deal will exceed 67 million US dollars over ten years.

Biotech: The Future of Saudi Pharma

Saudi Arabia is positioning itself as a global leader in the biotech industry. The National Biotechnology Strategy aims to make the country a biotech leader in the Middle East and North Africa (MENA) region by 2030 and becoming a major global biotech centre by 2040. The strategy provides a detailed roadmap to tackle critical health issues, speed up medical advancements, and improve patient care through genomics, precision medicine, and advanced therapeutics. It therefore seeks to create a local bio-manufacturing platform to increase biologics and biosimilars self-sufficiency and export potential. This strategy is expected to contribute USD 34.6 billion to the country’s non-oil GDP by 2040 and create 11,000 job opportunities.

The Prevailing PPP Model

Saudi Arabia’s Vision 2030 plan has been instrumental in activating the private sector’s participation in its healthcare transformation. The PPP model is being used to roll out new and more efficient healthcare infrastructures. While the government used to build, operate, and maintain hospitals, they now realise that the private sector can provide upfront investment and healthcare. The country delivered better services for the same or less cost because the private sector is more efficient and effective. In the future, this trend is expected to persist.

Conclusion:

To conclude, the Saudi Pharma Market 2024 promises growth and innovation. Strategic plans, local production, biotech initiatives, and the PPP model drive this evolution. This market transformation benefits not only the country but also global pharmaceutical and biotech players. Saudi Arabia’s strategic location makes it an appealing regional hub from which enterprises may serve other MENA markets.

Reference url

Recent Posts

oral health Africa
    

Oral Health in Africa: Promoting Collaborative Solutions

🦷 Is oral health taking a back seat in public health discussions in Africa?

A new article reveals alarming statistics about the high prevalence of untreated dental diseases across the continent and a critical shortage of oral health professionals. It emphasizes the urgent need for collaborative action among healthcare providers and policy-makers to integrate oral health into broader public health frameworks.

Discover how strengthening partnerships can pave the way for improved health outcomes and resource allocation in oral health.

#SyenzaNews #globalhealth #HealthEconomics

tislelizumab NSCLC treatment
        

Early Benefit Assessment of Tislelizumab NSCLC Treatment: Insights and Implications

🧐 How is the evolving treatment landscape for NSCLC affecting patient access to tislelizumab?

The German Federal Joint Committee (G-BA) has launched an early benefit assessment for tislelizumab as a second-line treatment for adults with advanced NSCLC. This assessment notably focuses on PD-L1 negative patients and highlights the need for additional data to substantiate its value amidst a shifting emphasis on first-line immunotherapy.

Explore the nuances of this assessment and its implications for future research and market access in the full article.

#SyenzaNews #oncology #MarketAccess

colorectal cancer screening
    

Advances in Colorectal Cancer Screening: Access and Cost

🚀 Is blood-based screening redefining colorectal cancer detection?

The Shield blood test offers a non-invasive alternative to colonoscopy—boosting screening uptake, but raising questions around effectiveness and value.

🔍 Discover how this innovation could reshape patient care, payer strategy, and health system costs.

#SyenzaNews #HealthcareInnovation #CostEffectiveness #DigitalTransformation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.